Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

REPL Replimune Group Inc.

交易中 12-19 13:32:07 EST

10.11

+0.42

+4.28%

最高10.14	最低9.68	成交量52.63万
今开9.73	昨收9.69	日振幅4.75%
总市值7.93亿	流通市值5.05亿	总股本7,844万
成交额522.13万	换手率1.05%	流通股本4,997万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":10.105,"timestamp":1766169121775,"preClose":9.69,"halted":0,"volume":526292,"delay":0,"floatShares":49968589,"shares":78443334,"eps":-3.467754,"marketStatus":"交易中","change":0.415,"latestTime":"12-19 13:32:07 EST","open":9.73,"high":10.14,"low":9.68,"amount":5221296.618303999,"amplitude":0.047472,"askPrice":10.11,"askSize":379,"bidPrice":10.1,"bidSize":613,"shortable":3,"etf":0,"ttmEps":-3.467754,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766178000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":9.69,"preHourTrading":{"tag":"盘前","latestPrice":9.72,"preClose":9.69,"latestTime":"08:43 EST","volume":4583,"amount":44705.758019,"timestamp":1766151804538},"postHourTrading":{"tag":"盘后","latestPrice":9.69,"preClose":9.69,"latestTime":"18:07 EST","volume":44275,"amount":429042.59,"timestamp":1766099250672},"volumeRatio":0.656361,"impliedVol":1.0774,"impliedVolPercentile":0.556},"requestUrl":"/m/hq/s/REPL","defaultTab":"news","newsList":[{"id":"1192482852","title":"Replimune Group第二季度净亏损8310万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192482852","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192482852?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:58","pubTimestamp":1763571497,"startTime":"0","endTime":"0","summary":"11月6日 - Replimune Group第二季度运营费用为8429.1万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2582484773","title":"Replimune Group, Inc.盘中异动 大幅拉升5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582484773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582484773?lang=zh_cn&edition=full","pubTime":"2025-11-12 00:10","pubTimestamp":1762877430,"startTime":"0","endTime":"0","summary":"北京时间2025年11月12日00时10分，Replimune Group, Inc.股票出现异动，股价大幅拉升5.05%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为1.11%。其相关个股中，Engene Holdings Inc C/Wts 31/10/2028  Cl A、Engene Holdings Inc.、Xbiotech Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aspire Biopharma Holdings, Inc.、Salarius Pharmaceuticals, Inc.较为活跃，换手率分别为2691.76%、356.53%、310.40%，振幅较大的相关个股有Engene Holdings Inc C/Wts 31/10/2028  Cl A、Quoin Pharmaceuticals Ltd、Engene Holdings Inc.，振幅分别为75.38%、58.48%、54.91%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511120010319762d726&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511120010319762d726&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2577652535","title":"Replimune Group, Inc.盘中异动 早盘股价大涨5.06%报8.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577652535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577652535?lang=zh_cn&edition=full","pubTime":"2025-10-23 21:42","pubTimestamp":1761226940,"startTime":"0","endTime":"0","summary":"北京时间2025年10月23日21时42分，Replimune Group, Inc.股票出现波动，股价急速上涨5.06%。截至发稿，该股报8.72美元/股，成交量45.7567万股，换手率0.59%，振幅4.23%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。消息层面，截至21时42分，《Leerink Partners上调Replimune至买入评级，上调目标价至13美元》资讯为影响Replimune Group, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102321422094d9d68b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102321422094d9d68b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTYX","BK4139","BK4007","REPL"],"gpt_icon":0},{"id":"1183771911","title":"异动解读 | Replimune Group股价盘中大涨5.20%，多家券商上调评级及目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1183771911","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183771911?lang=zh_cn&edition=full","pubTime":"2025-10-21 21:32","pubTimestamp":1761053557,"startTime":"0","endTime":"0","summary":"生物医药公司Replimune Group Inc今日股价表现强劲，盘中大涨5.20%，引起市场广泛关注。消息面上，多家知名券商对Replimune Group给予了积极评级。这些利好评级显示华尔街分析师对Replimune Group未来发展前景持乐观态度。分析人士认为，券商评级的上调可能反映出Replimune Group在肿瘤免疫疗法研发方面取得了积极进展。作为一家专注于开发新一代肿瘤溶解免疫疗法的生物技术公司，Replimune Group的研发成果对公司未来发展至关重要。投资者对公司潜力的认可推动了股价的强劲上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REPL"],"gpt_icon":0},{"id":"1143237081","title":"Replimune Group Inc：Piper Sandler将评级从中性上调至增持；目标价从8美元上调至13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143237081","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143237081?lang=zh_cn&edition=full","pubTime":"2025-10-21 12:17","pubTimestamp":1761020229,"startTime":"0","endTime":"0","summary":"Replimune Group Inc：Piper Sandler将评级从中性上调至增持；目标价从8美元上调至13美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"1113640990","title":"异动解读 | Replimune集团股价盘中飙升100%，皮肤癌新药申请获FDA接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1113640990","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113640990?lang=zh_cn&edition=full","pubTime":"2025-10-20 22:02","pubTimestamp":1760968944,"startTime":"0","endTime":"0","summary":"生物技术公司Replimune Group Inc周一股价表现亮眼，盘中大涨100.76%，引发市场广泛关注。这一显著涨幅主要源于该公司在新药开发方面取得重大进展。据悉，美国食品药品监督管理局已接受Replimune重新提交的实验性疗法RP1的审批申请。FDA此次接受申请为该药物的潜在批准铺平了道路，预计将于明年4月10日前对该药物做出决定。这一消息对Replimune来说意义重大。值得注意的是，在此利好消息公布之前，Replimune的股价今年以来已累计下跌62.8%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["REPL"],"gpt_icon":0},{"id":"1122482588","title":"生物技术公司Replimune盘初飙升，其新药审批申请获得FDA的接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1122482588","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122482588?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:57","pubTimestamp":1760968668,"startTime":"0","endTime":"0","summary":"接受了其皮肤癌药物重新提交的审批申请。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL"],"gpt_icon":0},{"id":"1162796164","title":"Replimune 股价在美国 FDA 接受皮肤癌药物潜在批准重新提交后翻倍，最新涨幅为106.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162796164","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162796164?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:39","pubTimestamp":1760967551,"startTime":"0","endTime":"0","summary":"Replimune 股价在美国 FDA 接受皮肤癌药物潜在批准的重新提交后，涨幅超过一倍，最新上涨106.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"1131372511","title":"Replimune Group股票在盘前上涨75.8%，因美国FDA接受皮肤癌药物的重新提交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1131372511","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131372511?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:30","pubTimestamp":1760959810,"startTime":"0","endTime":"0","summary":"Replimune Group股票在盘前上涨75.8%，因美国FDA接受了该公司皮肤癌药物的重新提交申请，从而为潜在批准铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"26c657bd6894c690b20c7751c141e52e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"1163806006","title":"新闻稿：Replimune在与FDA Type A会议后发布最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1163806006","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163806006?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:17","pubTimestamp":1758201435,"startTime":"0","endTime":"0","summary":"公司正在评估会议期间FDA提供的反馈意见，以确定下一步行动。目前，尚未确定在加速审批途径下的前进路径。Replimune首席执行官Sushil Patel博士表示：\"来自黑色素瘤医学界包括患者和医生的反馈，清楚地强调了晚期黑色素瘤存在的未满足医疗需求，以及在IGNYTE试验中观察到的RP1令人信服的获益风险特征。Replimune的专有RPx平台基于强效的HSV-1骨架，旨在最大化免疫原性细胞死亡和诱导全身抗肿瘤免疫反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","REPL","BK4585","BK4139","LU1815336091.USD","BK4588","LU0390134368.USD","BK4530","LU0757428866.USD","CRL"],"gpt_icon":0},{"id":"1127455245","title":"Replimune Group Inc.简报手册包含BLA数据的补充分析 并回应3期确认性试验设计相关意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1127455245","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127455245?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:16","pubTimestamp":1756815399,"startTime":"0","endTime":"0","summary":"Replimune Group Inc.简报手册包含BLA数据的补充分析 并回应3期确认性试验设计相关意见","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2558616803","title":"Replimune Group, Inc.8月11日成交额为2911.69万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558616803","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558616803?lang=zh_cn&edition=full","pubTime":"2025-08-12 13:45","pubTimestamp":1754977546,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，Replimune Group, Inc.成交额为2911.69万美元，成交额较昨日增加14.60%，当日成交量为596.14万股。Replimune Group, Inc.于2025年8月11日跌5.67%，报4.99美元，该股过去5个交易日跌12.61%，年初至今跌58.79%，过去60日跌28.82%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-11|2911.69万|14.60%|596.14万|#|2025-08-08|2540.82万|-18.75%|485.61万|#|2025-08-07|3127.00万|-27.40%|585.28万|#|2025-08-06|4307.33万|-13.88%|766.27万|#|2025-08-05|5001.33万|-59.04%|812.43万|Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812134549a4835db2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812134549a4835db2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"1165295263","title":"知名疫苗监管者重返FDA，部分生物科技公司盘前下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1165295263","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165295263?lang=zh_cn&edition=full","pubTime":"2025-08-11 18:12","pubTimestamp":1754907141,"startTime":"0","endTime":"0","summary":"疫苗和免疫疗法相关股票曾出现下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f378b42123c17fa480658121fcaf85bc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","CAPR","REPL"],"gpt_icon":0},{"id":"2558506264","title":"Replimune Group, Inc.8月8日成交额为2540.82万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558506264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558506264?lang=zh_cn&edition=full","pubTime":"2025-08-09 13:44","pubTimestamp":1754718289,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，Replimune Group, Inc.成交额为2540.82万美元，成交额较昨日减少18.75%，当日成交量为485.61万股。Replimune Group, Inc.于2025年8月8日跌3.47%，报5.29美元，该股过去5个交易日跌30.39%，年初至今跌56.32%，过去60日跌28.61%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-08|2540.82万|-18.75%|485.61万|#|2025-08-07|3127.00万|-27.40%|585.28万|#|2025-08-06|4307.33万|-13.88%|766.27万|#|2025-08-05|5001.33万|-59.04%|812.43万|#|2025-08-04|1.22亿|73.18%|2234.66万|Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809134457a47e669d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809134457a47e669d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2557485515","title":"Replimune Group, Inc.8月7日成交额为3127.00万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557485515","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557485515?lang=zh_cn&edition=full","pubTime":"2025-08-08 13:42","pubTimestamp":1754631734,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，Replimune Group, Inc.成交额为3127.00万美元，成交额较昨日减少27.40%，当日成交量为585.28万股。Replimune Group, Inc.于2025年8月7日跌0.36%，报5.48美元，该股过去5个交易日跌22.05%，年初至今跌54.75%，过去60日跌30.28%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-07|3127.00万|-27.40%|585.28万|#|2025-08-06|4307.33万|-13.88%|766.27万|#|2025-08-05|5001.33万|-59.04%|812.43万|#|2025-08-04|1.22亿|73.18%|2234.66万|#|2025-08-01|7051.46万|-49.59%|977.31万|Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808134222a47c7bb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808134222a47c7bb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2557517308","title":"Replimune Group, Inc.盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557517308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557517308?lang=zh_cn&edition=full","pubTime":"2025-08-06 21:57","pubTimestamp":1754488672,"startTime":"0","endTime":"0","summary":"北京时间2025年08月06日21时57分，Replimune Group, Inc.股票出现异动，股价快速下跌5.04%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，诺瓦瓦克斯医药、Biomx Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Bioxcel Therapeutics, Inc.、Biomx Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为432.75%、322.09%、31.71%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Fortrea Holdings Inc.、Biomx Inc.，振幅分别为45.15%、29.42%、24.94%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806215753a478e3d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806215753a478e3d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"gpt_icon":1},{"id":"2557652397","title":"Replimune Group, Inc.盘中异动 早盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557652397","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557652397?lang=zh_cn&edition=full","pubTime":"2025-08-05 21:32","pubTimestamp":1754400755,"startTime":"0","endTime":"0","summary":"北京时间2025年08月05日21时32分，Replimune Group, Inc.股票出现波动，股价大幅拉升5.08%。Replimune Group, Inc.股票所在的生物技术行业中，整体跌幅为3.08%。其相关个股中，Y-Mabs Therapeutics, Inc.、Shattuck Labs, Inc.、Adaptimmune Therapeutics Plc涨幅较大，Shattuck Labs, Inc.、Adaptimmune Therapeutics Plc、Cyclacel Pharmaceuticals, Inc.较为活跃，换手率分别为101.36%、75.15%、62.14%，振幅较大的相关个股有Plus Therapeutics, Inc.、Hyperion Defi, Inc.、Cellectis Ads Each Repr 1 Ord Spon，振幅分别为12.18%、10.81%、10.60%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080521323594d15ffd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080521323594d15ffd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","REPL"],"gpt_icon":1},{"id":"2557135207","title":"Replimune Group, Inc.8月4日成交额为1.22亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557135207","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557135207?lang=zh_cn&edition=full","pubTime":"2025-08-05 13:29","pubTimestamp":1754371793,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，Replimune Group, Inc.成交额为1.22亿美元，成交额较昨日增加73.18%，当日成交量为2234.66万股。Replimune Group, Inc.于2025年8月4日跌24.87%，报5.71美元，该股过去5个交易日涨80.13%，年初至今跌52.85%，过去60日跌20.25%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-04|1.22亿|73.18%|2234.66万|#|2025-08-01|7051.46万|-49.59%|977.31万|#|2025-07-31|1.40亿|-90.15%|1968.74万|#|2025-07-30|14.20亿|1538.30%|2.02亿|#|2025-07-29|8668.38万|227.23%|2337.51万|Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805133004a6d3c57e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805133004a6d3c57e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"gpt_icon":1},{"id":"2556812448","title":"Replimune Group, Inc.盘中异动 早盘急速下挫5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556812448","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556812448?lang=zh_cn&edition=full","pubTime":"2025-08-01 21:48","pubTimestamp":1754056083,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日21时48分，Replimune Group, Inc.股票出现波动，股价急速下跌5.19%。截至发稿，该股报6.67美元/股，成交量97.1479万股，换手率1.25%，振幅3.20%。Replimune Group, Inc.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，天境生物、4D Molecular Therapeutics, Inc.、Bioxcel Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为920.55%、120.20%、112.85%，振幅较大的相关个股有Neurosense Therapeutics Ltd.、天境生物、Bioxcel Therapeutics, Inc.，振幅分别为29.12%、22.89%、22.14%。Replimune Group, Inc.公司简介：Replimune Group Inc 是一家临床阶段的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801214803972d0716&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801214803972d0716&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["REPL","BK4139"],"gpt_icon":1},{"id":"1191719360","title":"FDA现重大人事变动！部分生物制药股飙升，REPL飙涨逾100%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191719360","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191719360?lang=zh_cn&edition=full","pubTime":"2025-07-30 23:31","pubTimestamp":1753889491,"startTime":"0","endTime":"0","summary":"可能有助于缓解监管压力。","market":"us","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df3f0e1d74b88554715c54dc285ed300","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1323856.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA现重大人事变动！部分生物制药股飙升，REPL飙涨逾100%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["REPL","CAPR","SRPT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0182},{"period":"1month","weight":0.1087},{"period":"3month","weight":2.0047},{"period":"6month","weight":0.0453},{"period":"1year","weight":-0.169},{"period":"ytd","weight":-0.1998}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Replimune Group, Inc.于2015年在特拉华州注册成立。该公司是一家临床阶段的生物技术公司，致力于应用他们在溶瘤免疫治疗领域的领先专业技术，改变癌症患者的生活。使用该公司专有的Immulytic平台来设计和开发旨在最大限度激活免疫系统对抗癌症的候选产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.023803},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.070613},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.10067},{"month":4,"riseRate":0.571429,"avgChangeRate":0.118692},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.048711},{"month":6,"riseRate":0.857143,"avgChangeRate":0.223071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087403}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Replimune Group Inc.(REPL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Replimune Group Inc.(REPL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}